Recent Company News

• 09:17 AM ET Dec 04, 2025
  

  FDA to lower the number of trials required for drugs, other medical products - STAT News

• 08:13 AM ET Dec 04, 2025
  

  StreetAccount Themes Headlines (4-Dec)

• 06:05 AM ET Dec 03, 2025
  

  StreetAccount Macro Headlines:

• 02:05 AM ET Dec 04, 2025
  

  European macro headlines:

• 02:52 PM ET Dec 03, 2025
  

  Afternoon Headlines:

• 10:46 AM ET Dec 03, 2025
  

  Akero Therapeutics' shareholders approve pending purchase by Novo Nordisk - 8-K ($54.65, +0.16)

• 10:34 AM ET Dec 03, 2025
  

  FTC grants antitrust clearance for Novo Nordisk's purchase of Akero Therapeutics ($54.61, +0.12)

• 04:05 AM ET Dec 02, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 08:34 AM ET Dec 01, 2025
  

  Omeros Corporation closes asset purchase and license agreement with Novo Nordisk for clinical-stage MASP-3 inhibitor zaltenibart (OMS906) ($9.69, 0.00)